Valuation: REGENXBIO Inc.

Market Cap 530M 462M 436M 396M 743M 50.86B 746M 5.23B 2.02B 25.86B 1.99B 1.95B 83.21B P/E 2026 *
-2.44x
P/E 2027 * -3x
Enterprise Value 521M 455M 429M 390M 730M 50.03B 733M 5.14B 1.98B 25.43B 1.96B 1.92B 81.84B EV / Sales 2026 *
3.11x
EV / Sales 2027 * 2.69x
Free-Float
93.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week-5.86%
Current month-15.47%
1 month-33.19%
3 months+2.95%
6 months-3.95%
Current year-44.24%
1 week 7.64
Extreme 7.6359
8.75
1 month 7.64
Extreme 7.6359
11.16
Current year 5.46
Extreme 5.455
16.19
1 year 5.46
Extreme 5.455
16.19
3 years 5.04
Extreme 5.035
28.8
5 years 5.04
Extreme 5.035
44.85
10 years 5.04
Extreme 5.035
85.1
Manager TitleAgeSince
Chief Executive Officer 64 2024-06-30
Director of Finance/CFO 45 2024-09-15
Chief Tech/Sci/R&D Officer 53 2025-02-28
Director TitleAgeSince
Chairman 78 2020-06-30
Chairman 51 2024-06-30
Director/Board Member 76 2015-10-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Tax

Chief Technology Officer

-234 0.0004%
9/1/26 Tax

Chief Financial Officer

-4,902 0.0074%
8/27/26 Buy

Director

53,407 0.0818%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-5.86%-9.67%-55.14% 530M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.76%+0.90%+31.41%+181.09% 27.54B
Weighted average by Cap. -0.48%+1.43%+35.29%+147.33%

Financials

2026 *2027 *
Net sales 168M 146M 138M 125M 235M 16.1B 236M 1.65B 639M 8.19B 630M 616M 26.34B 217M 189M 179M 162M 304M 20.83B 305M 2.14B 826M 10.59B 815M 797M 34.07B
Net income -176M -154M -145M -132M -247M -16.89B -248M -1.74B -670M -8.59B -661M -647M -27.64B -200M -175M -165M -150M -280M -19.21B -282M -1.97B -762M -9.77B -752M -735M -31.43B
Net Debt -8.72M -7.6M -7.18M -6.52M -12.21M -837M -12.26M -85.99M -33.18M -425M -32.75M -32.02M -1.37B 53.61M 46.75M 44.14M 40.09M 75.11M 5.14B 75.42M 529M 204M 2.62B 201M 197M 8.42B
Logo REGENXBIO Inc.
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Employees
371
Date Price Change Volume
26-09-18 US$8.030 -2.25% 3,375,140
26-09-17 US$8.215 +2.94% 1,808,112
26-09-16 US$7.980 +0.44% 1,231,601
26-09-15 US$7.945 -8.57% 1,427,119
26-09-14 US$8.690 +1.88% 858,446
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.030USD
Average target price
23.73USD
Spread / Average Target
+195.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGNX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!